Melinta Therapeutics Announces Vabomere™ (meropenem and vaborbactam) Granted New Technology Add-On Payment by CMS
03. August 2018 13:31 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Aug. 03, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...
Melinta Therapeutics to Report Second Quarter 2018 Financial Results on August 7, 2018
11. Juli 2018 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., July 11, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...
Melinta Therapeutics to Present at the JMP Securities Life Sciences Conference
13. Juni 2018 16:05 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., June 13, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...
Melinta Therapeutics Demonstrates Breadth of Commercial and Clinical Programs with 20 Presentations at ASM Microbe 2018
31. Mai 2018 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., May 31, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious...
Melinta Therapeutics Announces Closing of Underwritten Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock
29. Mai 2018 16:05 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., May 29, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious...
Melinta Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference
24. Mai 2018 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., May 24, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious...
Melinta Therapeutics Announces Pricing of Public Offering of Common Stock
23. Mai 2018 21:07 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., May 23, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious...
Melinta Therapeutics Announces Proposed Offering of Common Stock
21. Mai 2018 16:10 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., May 21, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious...
Melinta Therapeutics Launches New Antibiotic Stewardship Program to Combat Growing Threat of Antimicrobial Resistance
11. Mai 2018 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., May 11, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious...
Melinta Therapeutics Reports First Quarter 2018 Financial Results
08. Mai 2018 16:01 ET
|
Melinta Therapeutics
Strong Product Sales Performance Across Entire Portfolio Continuing to Optimize Operations to Achieve Cost Synergies Important Achievements for Development and Discovery Efforts Including CARB-X...